MANKIND PHARMA
|
The Current P/E Ratio of MANKIND PHARMA is 45.47.
| Share Price | ₹2,477.1 | Nov 03,2026 |
| Market Cap | ₹102,304.2 Cr | |
| Earnings-TTM | ₹2,249.7 Cr | TTM-Consolidated Results |
| Price/Earnings | 45.47x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of MANKIND PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹102,304.2 Cr] as on Nov 03,2026
(/) Earnings [ ₹2,249.7 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 45.47x ]
Thus, for MANKIND PHARMA , the investors are currently willing to pay 45.47 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of MANKIND PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of MANKIND PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of MANKIND PHARMA
PE Ratio Performance Analysis for MANKIND PHARMA
- MANKIND PHARMA 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 28.32x.
- MANKIND PHARMA 's operated at median p/e ratio of 43.29x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, MANKIND PHARMA 's p/e ratio peaked in Mar2025 at 50.22x.
- MANKIND PHARMA 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does MANKIND PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| MANKIND PHARMA | 2,249.69 | 45.47 | 102,304.2 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,037.20 | 38.52 | 425,150.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 91.03 | 266,265.0 |
| TORRENT PHARMACEUTICALS LTD | 2,099.00 | 83.99 | 176,300.0 |
| CIPLA LTD | 2,868.29 | 39.21 | 112,474.0 |
| DR REDDYS LABORATORIES LTD | 2,759.70 | 41.44 | 114,351.0 |
| LUPIN LTD | 5,551.01 | 16.57 | 92,007.4 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 27.51 | 123,591.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 26.33 | 97,756.7 |
| LAURUS LABS LTD | 1,333.75 | 93.98 | 125,352.0 |
| BIOCON LTD | 416.40 | 134.38 | 55,955.6 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs MANKIND PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 16.57x |
| Max industry PE | 134.38x |
| Median industry PE | 41.44x |
| Average industry PE | 58.04x |
You may also like the below Video Courses